Pera M F, Köberle B, Masters J R
Department of Zoology, Oxford University, UK.
Br J Cancer. 1995 May;71(5):904-6. doi: 10.1038/bjc.1995.176.
Metastatic testicular germ cell tumours are cured in approximately 85% of patients using cisplatin-based combination chemotherapy. Patients who fail to respond have a poor prognosis, and there is a need for more effective treatments for cisplatin-resistant disease. In this study, it is shown that two of four cell lines derived from human non-seminomatous testicular germ cell tumours are exceptionally sensitive to temozolomide, a new imidazotetrazine which can cross the blood-brain barrier in mice. In addition, three pairs of cisplatin-resistant sublines show little cross-resistance to temozolomide. These data suggest that temozolomide might have activity against non-seminomatous testicular germ cell tumours which have relapsed following cisplatin-containing chemotherapy, and could have a role in the treatment of patients with metastatic lesions in the brain.
使用以顺铂为基础的联合化疗，约85%的转移性睾丸生殖细胞肿瘤患者可被治愈。对治疗无反应的患者预后较差，因此需要针对顺铂耐药疾病的更有效治疗方法。本研究表明，源自人类非精原性睾丸生殖细胞肿瘤的四个细胞系中有两个对替莫唑胺异常敏感，替莫唑胺是一种新型咪唑并四嗪，在小鼠体内可穿过血脑屏障。此外，三对顺铂耐药亚系对替莫唑胺几乎没有交叉耐药性。这些数据表明，替莫唑胺可能对含顺铂化疗后复发的非精原性睾丸生殖细胞肿瘤有活性，并且可能在治疗脑部有转移性病变的患者中发挥作用。
